The global novel antibody therapies market represents one of the most transformative segments of modern biopharmaceutical innovation. In 2024, the market was valued at USD 313,459 million and is projected to reach USD 765,093.7 million by 2032, expanding at a robust compound annual growth rate (CAGR) of 11.8% over the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Novel Antibody Therapies Market Size 2024
USD 313,459 million
Novel Antibody Therapies Market , CAGR
11.8%
Novel Antibody Therapies Market Size 2032
USD 765,093.7 million
Novel Antibody Therapies Market Insights
Market growth is driven by rising adoption of targeted biologics in oncology and autoimmune diseases, where monoclonal antibodies dominate with over 70% segment share, supported by long treatment durations, high clinical efficacy, and expanding use in combination regimens.
Key market trends include rapid advancement of antibody-drug conjugates and multispecific antibodies, while competitive intensity remains high among global leaders leveraging pipeline depth, lifecycle extensions, and strategic collaborations to defend share against biosimilar pressure.
Market restraints include high development and manufacturing costs, complex biologics supply chains, and reimbursement pressure, which limit access in cost-sensitive healthcare systems and emerging markets.
Regionally, North America leads with 44% share, followed by Europe at 29%, Asia-Pacific at 21%, and Rest of the World at 6%, with Asia-Pacific showing the fastest growth due to expanding biologics infrastructure.
The novel antibody therapies market by type is dominated by monoclonal antibodies (mAbs), which account for the majority of total market revenue due to their broad clinical applicability and long-standing regulatory acceptance. Within mAbs, oncology represents the dominant sub-segment, holding the largest market share, driven by extensive use of immune checkpoint inhibitors, tumor-targeting antibodies, and combination regimens in solid tumors and hematologic malignancies. Autoimmune diseases form the second-largest mAbs application, supported by chronic treatment demand. Infectious disease and other mAbs contribute steadily, while antibody-drug conjugates (ADCs) represent the fastest-evolving segment, driven by precision cytotoxic delivery and expanding oncology pipelines.
For instance, Roche’s oncology mAb portfolio includes atezolizumab, which has been evaluated across more than 40 Phase I–III clinical trials covering lung, breast, and urologic cancers, with cumulative patient enrollment exceeding 23,000 subjects, underscoring the scale of mAb adoption in oncology.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
By end-use, hospitals constitute the dominant sub-segment, capturing the largest share of the novel antibody therapies market due to their central role in administering complex biologics, oncology infusions, and inpatient immunotherapy protocols. High patient volumes, advanced infusion infrastructure, and multidisciplinary oncology care models reinforce hospital dominance. Specialty centers including oncology clinics and immunology-focused treatment centers represent a rapidly expanding segment, driven by decentralization of care, outpatient biologics administration, and rising adoption of targeted antibody therapies. Growth in specialty centers is further supported by improved cold-chain logistics, specialized clinician expertise, and patient preference for focused, lower-acuity treatment settings.
For instance, The US Oncology Network–affiliated community oncology practices collectively support more than 700 sites of care across the United States. These locations enable advanced infusion services for more than 1.6 million patients annually while maintaining electronic regimen standardization across more than 3,300 affiliated providers.
Key Growth Drivers
Expanding Clinical Adoption Across Oncology and Chronic Diseases
The rapid expansion of clinical adoption across oncology, autoimmune, and inflammatory diseases is a primary growth driver for novel antibody therapies. In oncology, antibodies are increasingly used as backbone therapies due to their high target specificity, favorable safety profiles, and compatibility with combination regimens involving chemotherapy, radiotherapy, and cell-based therapies. In autoimmune and inflammatory diseases, long-term disease management requirements favor biologics over small molecules, supporting sustained demand. The growing prevalence of cancer and immune-mediated disorders globally, combined with earlier diagnosis and longer treatment durations, further accelerates uptake. Physicians increasingly prefer antibody-based therapies for their predictable pharmacokinetics and well-established clinical outcomes, reinforcing their central role in modern treatment protocols.
For instance, Bristol Myers Squibb’s nivolumab has been studied across more than 90 Phase I–III oncology trials, with cumulative enrollment exceeding 35,000 patients, supporting its use as a core component in combination regimens for melanoma, lung cancer, renal cell carcinoma, and hematologic malignancies.
Advancements in Antibody Engineering and Platform Technologies
Continuous innovation in antibody engineering significantly drives market growth by improving efficacy, durability, and safety. Advances such as Fc-region optimization, half-life extension technologies, bispecific antibody formats, and site-specific conjugation methods have expanded the functional capabilities of antibodies. These innovations enable enhanced immune engagement, improved tumor penetration, and reduced off-target toxicity. Platform-based development approaches also shorten development timelines and improve pipeline productivity, encouraging sustained R&D investment. Improved manufacturability and scalability of next-generation antibodies further support commercialization, allowing developers to move complex molecules from clinical development to large-scale production with greater efficiency and consistency.
For instance, AstraZeneca’s half-life–extended antibody platform incorporates Fc mutations that increase neonatal Fc receptor (FcRn) binding affinity, enabling antibodies such as tixagevimab and cilgavimab to achieve serum half-lives exceeding 80 days in humans, reducing dosing frequency while maintaining sustained neutralizing activity.
Strong Pipeline Expansion and Regulatory Momentum
The robust expansion of clinical pipelines and supportive regulatory pathways is another major growth driver. Novel antibody therapies continue to dominate late-stage development portfolios across large pharmaceutical companies and biotechnology firms. Accelerated approval pathways, orphan drug designations, and breakthrough therapy status have reduced time-to-market for innovative antibodies addressing unmet medical needs. Regulatory familiarity with antibody platforms lowers approval risk compared to novel drug modalities, encouraging sustained investment. Additionally, lifecycle management strategies including label expansions, new indications, and combination approvals extend commercial longevity and revenue potential for approved antibody products.
Key Trends & Opportunities
Rapid Growth of Antibody-Drug Conjugates and Multispecific Antibodies
Antibody-drug conjugates (ADCs) and multispecific antibodies represent a major trend and opportunity within the novel antibody therapies market. These formats combine precise targeting with enhanced functional activity, enabling selective delivery of cytotoxic agents or immune modulation. Their growing use in oncology reflects strong clinical efficacy in resistant and late-stage cancers. Advances in linker chemistry, payload diversity, and conjugation stability continue to expand therapeutic windows. Multispecific antibodies further offer opportunities in immune redirection and combination targeting within a single molecule, reducing treatment complexity and improving patient outcomes.
For instance, Daiichi Sankyo’s DXd ADC technology employs a topoisomerase I inhibitor payload with a drug-to-antibody ratio of approximately 8, coupled via a cleavable tetrapeptide linker that remains stable in systemic circulation yet efficiently releases payload in tumor cells following lysosomal processing.
Expansion into Earlier Lines of Therapy and New Indications
A key opportunity lies in the expanding use of antibody therapies in earlier treatment lines and non-oncology indications. Antibodies are increasingly evaluated as first-line or maintenance therapies rather than last-resort options. This shift significantly increases treatment duration and addressable patient populations. Additionally, growing exploration of antibody applications in neurology, infectious diseases, and rare disorders opens new revenue streams. Improved blood-brain barrier penetration strategies and antiviral antibody platforms further broaden the clinical scope of antibody-based interventions.
For instance, Vir Biotechnology’s monoclonal antibody sotrovimab was engineered using Fc modifications to extend serum half-life and maintained in vitro neutralization activity at nanomolar concentrations against multiple viral variants, enabling single-dose intravenous administration for acute viral infection management.
Key Challenges
High Development, Manufacturing, and Treatment Costs
Despite strong demand, high development and manufacturing costs remain a significant challenge. Antibody therapies require complex biologics manufacturing infrastructure, stringent quality controls, and cold-chain logistics, contributing to elevated production expenses. These costs translate into high treatment prices, limiting patient access in cost-sensitive healthcare systems. Payer scrutiny, reimbursement pressures, and pricing negotiations increasingly influence market uptake, particularly in emerging economies. Cost containment without compromising quality remains a critical hurdle for manufacturers.
Competitive Intensity and Biosimilar Pressure
The growing entry of biosimilars and increased competition within established antibody classes pose another key challenge. As patents expire for blockbuster monoclonal antibodies, biosimilar alternatives intensify price competition and erode branded market share. This pressure forces originator companies to invest heavily in next-generation antibodies and lifecycle extensions to sustain differentiation. Additionally, crowded pipelines increase the risk of clinical failure and commercialization challenges, making strategic positioning and clinical differentiation essential for long-term success.
Regional Analysis
North America
North America dominates the novel antibody therapies market, accounting for approximately 42-45% of global market share. The region’s leadership is driven by strong biopharmaceutical R&D infrastructure, high biologics adoption rates, and early access to innovative antibody platforms. The United States represents the largest contributor due to high oncology prevalence, rapid uptake of next-generation monoclonal antibodies and ADCs, and favorable reimbursement for specialty biologics. Robust regulatory pathways, extensive clinical trial activity, and sustained investment by leading pharmaceutical companies further support market maturity. Canada contributes steadily through expanding biologics manufacturing and rising use of antibody therapies in chronic disease management.
Europe
Europe holds an estimated 28-30% share of the global novel antibody therapies market, supported by well-established healthcare systems and strong regulatory harmonization. Countries such as Germany, France, the United Kingdom, and Italy lead regional demand due to widespread adoption of monoclonal antibodies in oncology and autoimmune disorders. The region benefits from public healthcare coverage that supports access to high-cost biologics, alongside growing bioscience research capabilities. Increased approvals of innovative antibodies and expanding use of ADCs in cancer treatment strengthen market growth. However, pricing controls and biosimilar penetration influence competitive dynamics across major European markets.
Asia-Pacific
Asia-Pacific represents the fastest-growing regional market, accounting for approximately 20-22% of global market share. Growth is driven by rising cancer incidence, expanding healthcare access, and increasing investment in biologics manufacturing across China, Japan, South Korea, and India. Governments in the region actively support domestic antibody development through funding initiatives and regulatory reforms. Japan remains a mature biologics market, while China shows rapid expansion due to strong local pipelines and accelerated approvals. Increasing clinical trial activity and growing adoption of advanced antibody therapies in tertiary hospitals further reinforce regional growth momentum.
Rest of the World (RoW)
The Rest of the World region, including Latin America, the Middle East, and Africa, accounts for approximately 5-8% of the global novel antibody therapies market. Market growth is supported by gradual improvements in healthcare infrastructure, rising awareness of biologic treatments, and expanding access to oncology care. Brazil, Mexico, and select Middle Eastern countries lead regional adoption, particularly in hospital-based antibody administration. However, limited reimbursement coverage, high therapy costs, and constrained cold-chain logistics restrict broader penetration. Despite these challenges, increasing government healthcare spending and international partnerships are expected to improve long-term market accessibility.
Novel Antibody Therapies Market Segmentations:
By Type
Monoclonal Antibodies (mAbs)
Oncology
Autoimmune Diseases
Infectious Diseases
Other Monoclonal Antibodies (mAbs)
Antibody-Drug Conjugates (ADCs)
By End-Use
Hospitals
Specialty Centers
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Competitive Landscape
The competitive landscape of the novel antibody therapies market is characterized by intense innovation, strong pipeline depth, and strategic positioning by global pharmaceutical and biotechnology leaders. Large multinational companies dominate the market through extensive portfolios of monoclonal antibodies, antibody-drug conjugates, and next-generation engineered formats, supported by vertically integrated R&D and biologics manufacturing capabilities. Competition increasingly centers on clinical differentiation, target novelty, and expansion into earlier lines of therapy rather than first-to-market advantage alone. Strategic collaborations, licensing agreements, and acquisitions are widely used to access emerging antibody platforms, accelerate development timelines, and mitigate R&D risk. At the same time, mid-size biotechnology firms play a critical role in advancing first-in-class antibodies, often becoming acquisition targets following late-stage success. The landscape is further shaped by biosimilar entry for mature antibodies, prompting originator companies to invest in lifecycle extensions, combination therapies, and next-generation constructs to sustain long-term competitiveness.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In May 2025, AbbVie received FDA approval in the United States for telisotuzumab vedotin (Emrelis), a c-Met-directed antibody-drug conjugate for non-small cell lung cancer, marking a significant regulatory milestone for its ADC pipeline.
In March 2025, AstraZeneca announced its planned acquisition of EsoBiotec, a biotech specializing in rapid in-body immune cell modification technologies, aiming to bolster its capabilities in cell therapies relevant to cancer and autoimmune disease programs complementary to antibody therapeutic strategies.
Report Coverage
The research report offers an in-depth analysis based on Type, End-Useand Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global Novel Antibody Therapies Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Type
6.1. Monoclonal Antibodies (mAbs)
6.1.1. Oncology
6.1.1.1. Market Trends
6.1.1.2. Market Forecast
6.1.1.3. Revenue Share
6.1.1.4. Revenue Growth Opportunity
6.1.2. Autoimmune Diseases
6.1.2.1. Market Trends
6.1.2.2. Market Forecast
6.1.2.3. Revenue Share
6.1.2.4. Revenue Growth Opportunity
6.1.3. Infectious Diseases
6.1.3.1. Market Trends
6.1.3.2. Market Forecast
6.1.3.3. Revenue Share
6.1.3.4. Revenue Growth Opportunity
6.1.4. Other Monoclonal Antibodies (mAbs)
6.1.4.1. Market Trends
6.1.4.2. Market Forecast
6.1.4.3. Revenue Share
6.1.4.4. Revenue Growth Opportunity
6.2. Antibody-Drug Conjugates (ADCs)
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
7. Market Breakup by End-Use
7.1. Hospitals
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Specialty Centers
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity 8. Market Breakup by Region
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Asia-Pacific
8.2.1. China
8.2.2. Japan
8.2.3. India
8.2.4. South Korea
8.2.5. Australia
8.2.6. Indonesia
8.2.7. Others
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. United Kingdom
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Others
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Others
8.5. Middle East and Africa
8.5.1. Market Trends
8.5.2. Market Breakup by Country
8.5.3. Market Forecast 9. SWOT Analysis
9.1. Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats 10. Value Chain Analysis 11. Porter’s Five Forces Analysis
11.1. Overview
11.2. Bargaining Power of Buyers
11.3. Bargaining Power of Suppliers
11.4. Degree of Competition
11.5. Threat of New Entrants
11.6. Threat of Substitutes 12. Price Analysis 13. Competitive Landscape
13.1. Market Structure
13.2. Key Players
13.3. Profiles of Key Players
13.3.1. AstraZeneca
13.3.2. AbbVie, Inc.
13.3.3. Amgen Inc.
13.3.4. Bristol-Myers Squibb Company
13.3.5. F. Hoffmann-La Roche Ltd.
13.3.6. Johnson & Johnson Services, Inc.
13.3.7. Merck & Co., Inc.
13.3.8. Novartis AG
13.3.9. Regeneron Pharmaceuticals Inc.
13.3.10. Seagen 14. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Novel antibody therapies, and what is its projected size in 2032?
The market was valued at USD 313,459 million in 2024 and is projected to reach USD 765,093.7 million by 2032.
At what Compound Annual Growth Rate is the Novel antibody therapies market projected to grow between 2024 and 2032?
The market is expected to grow at a CAGR of 11.8% during the forecast period.
Which Novel antibody therapies segment held the largest share in 2024?
Monoclonal antibodies (mAbs) held the largest share, driven primarily by strong demand in oncology and autoimmune diseases.
What are the primary factors fueling the growth of the Novel antibody therapies market?
Key factors include rising cancer prevalence, expanding use in chronic diseases, advancements in antibody engineering, and strong regulatory support.
Who are the leading companies in the Novel antibody therapies market?
Major players include Roche, AbbVie, Amgen, Bristol-Myers Squibb, Johnson & Johnson, Merck, Regeneron, Novartis, AstraZeneca, and Seagen.
Which region commanded the largest share of the Novel antibody therapies market in 2024?
North America led the market with approximately 44% share, supported by advanced R&D infrastructure and high biologics adoption.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The global combination therapies in aesthetics market was valued at USD 3,690 million in 2024 and is projected to reach USD 6,880.69 million by 2032, expanding at a compound annual growth rate (CAGR) of 8.1% during the forecast period.
The commercial aquaculture vaccines market was valued at USD 471 million in 2024 and is projected to reach USD 845.93 million by 2032, expanding at a compound annual growth rate (CAGR) of 7.6% during the forecast period.
The global bone growth stimulator market was valued at USD 1,890 million in 2024 and is projected to reach USD 3,058.14 million by 2032, expanding at a compound annual growth rate (CAGR) of 6.2% during the forecast period.
The global antioxidants market was valued at USD 4,095.8 million in 2024 and is anticipated to reach USD 6,657.29 million by 2032, expanding at a CAGR of 6.26% during the forecast period.
US Pharma R&D Outsourcing Market size was valued at USD 30,916.90 Million in 2024 and is anticipated to reach USD 67,782.11 Million by 2032, at a CAGR of 10.31% during the forecast period.
UAE Over-the-Counter (OTC) Pharmaceuticals Market size was valued at USD 2,913 million in 2024 and is anticipated to reach USD 4,110.63 million by 2032, at a CAGR of 4.4% during the forecast period.
The Prostatic Catheter Market size was valued at USD 199 million in 2024 and is anticipated to reach USD 309.44 million by 2032, at a CAGR of 5.7% during the forecast period.
The Rapid Microbiology Tests Market size was valued at USD 6,178 million in 2024 and is anticipated to reach USD 10496.15 million by 2032, at a CAGR of 6.85 % during the forecast period.
The Reversible Airway Diseases Treatment Market size was valued at USD 85,518 million in 2024 and is anticipated to reach USD 143671.9 million by 2032, at a CAGR of 6.7 % during the forecast period.
The RNA Targeting Small Molecule Drug Discovery Market size was valued at USD 1,723 million in 2024 and is anticipated to reach USD 8852.98 million by 2032, at a CAGR of 22.7 % during the forecast period.
The Rare Disease Clinical Trials Market size was valued at USD 12,949 million in 2024 and is anticipated to reach USD 21592.72 million by 2032, at a CAGR of 6.6 % during the forecast period.
The Rare Disease Genetic Testing Market size was valued at USD 1,197 million in 2024 and is anticipated to reach USD 3703.24 million by 2032, at a CAGR of 15.16 % during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
